drugset / Trial / NCT01447225
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the safety and tolerability of escalating doses of MM-121 + certain anticancer therapies
Timeline
- Start
- 2011-10
- Primary completion
- 2013-11
- Completion
- 2014-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabazitaxel | Other / unclassified | 20 mg/m2 | Intravenous |
| Subject | Cabazitaxel | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1250 mg/m2 | Intravenous |
| Subject | Seribantumab | Monoclonal antibody | 12 mg/kg | Intravenous |
| Subject | Seribantumab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Background | Carboplatin | Small molecule | 6 unknown | — |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |